Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 GRIA1 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
2 GRIA1 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
3 GRIA1 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
4 GRIA1 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
5 GRIA2 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
6 GRIA2 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
7 GRIA2 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D02696 Talampanel [2] 2, 6
8 GRIA2 [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08964 Perampanel [3] 2, 6, 144
9 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
10 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
11 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
12 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
13 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
14 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
15 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
16 GRIN1 [8] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
17 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
18 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
19 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
20 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
21 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
22 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
23 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
24 GRIN2A [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
25 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
26 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
27 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07058 Acamprosate [2] 6, 206
28 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07283 Esketamine [3] 2, 4, 70
29 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D07441 Amantadine [4] 6, 8, 13, 127
30 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
31 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
32 GRIN2B [9] Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus D09917 Latrepirdine [1] 8
33 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
34 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
35 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
36 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
37 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
38 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
39 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
40 GRIN2C [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
41 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D00775 Riluzole [9] 2, 3, 5, 8, 13, 17, 18, 203, 206
42 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D03742 Dextromethorphan [11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
43 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07058 Acamprosate [2] 6, 206
44 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07283 Esketamine [3] 2, 4, 70
45 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D07441 Amantadine [4] 6, 8, 13, 127
46 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
47 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D08174 Memantine [8] 2, 6, 8, 13, 49, 127, 205, 206
48 GRIN2D [6] Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction D09917 Latrepirdine [1] 8
49 PPP3CA [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
50 PPP3CA [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
51 PPP3CA [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
52 PPP3CA [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
53 PPP3CA [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [2] 49, 222
54 PPP3CB [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
55 PPP3CB [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
56 PPP3CB [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
57 PPP3CB [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
58 PPP3CB [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [2] 49, 222
59 PPP3CC [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
60 PPP3CC [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
61 PPP3CC [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
62 PPP3CC [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
63 PPP3CC [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [2] 49, 222
64 PPP3R1 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
65 PPP3R1 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
66 PPP3R1 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
67 PPP3R1 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
68 PPP3R1 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [2] 49, 222
69 PPP3R2 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00107 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
70 PPP3R2 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D00184 Cyclosporine [44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
71 PPP3R2 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D05480 Pimecrolimus [1] 160
72 PPP3R2 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D08556 Tacrolimus [34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
73 PPP3R2 [16] MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer D09033 Voclosporin [2] 49, 222
74 PRKCB [29] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, NF-kappa B signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Melanogenesis, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, Salivary secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Non-small cell lung cancer D11935 Enzastaurin [1] 168
75 MAP2K1 [41] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib [1] 34
76 MAP2K1 [41] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
77 MAP2K1 [41] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib [1] 280
78 MAP2K1 [41] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib [1] 34
79 MAP2K1 [41] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11675 Mirdametinib [1] 34
80 MAP2K2 [34] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09666 Selumetinib [1] 34
81 MAP2K2 [34] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10175 Trametinib [4] 2, 34, 279, 280
82 MAP2K2 [34] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10405 Cobimetinib [1] 280
83 MAP2K2 [34] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10604 Binimetinib [1] 34
84 MAP2K2 [34] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11675 Mirdametinib [1] 34
85 RAF1 [36] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08524 Sorafenib [2] 34, 86
86 BRAF [20] MAPK signaling pathway, Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer D08524 Sorafenib [2] 34, 86
87 BRAF [20] MAPK signaling pathway, Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer D10064 Dabrafenib [1] 34
88 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D00349 Isradipine [1] 6
89 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D00437 Nifedipine [2] 50, 81
90 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D00537 Topiramate [6] 6, 97, 140, 144, 156, 193
91 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D01173 Cilnidipine [1] 67
92 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D01908 Nilvadipine [1] 90
93 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D02356 Verapamil [4] 58, 96, 140, 167
94 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D07450 Amlodipine [4] 13, 51, 67, 298
95 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D07845 Diltiazem [3] 51, 58, 86
96 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D08270 Nicardipine [2] 70, 86
97 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D08340 Perhexiline [2] 58, 272
98 CACNA1C [11] MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases D08441 Propiverine [1] 226